GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Percheron Therapeutics Ltd (ASX:PER) » Definitions » ROE % Adjusted to Book Value

Percheron Therapeutics (ASX:PER) ROE % Adjusted to Book Value : -21.89% (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Percheron Therapeutics ROE % Adjusted to Book Value?

Percheron Therapeutics's ROE % for the quarter that ended in Dec. 2023 was -71.80%. Percheron Therapeutics's PB Ratio for the quarter that ended in Dec. 2023 was 3.28. Percheron Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -21.89%.


Percheron Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Percheron Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Percheron Therapeutics ROE % Adjusted to Book Value Chart

Percheron Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.58 -8.06 -18.49 -18.61 -14.50

Percheron Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.74 -14.04 -23.89 -21.89 -13.08

Competitive Comparison of Percheron Therapeutics's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Percheron Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Percheron Therapeutics's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Percheron Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Percheron Therapeutics's ROE % Adjusted to Book Value falls into.



Percheron Therapeutics ROE % Adjusted to Book Value Calculation

Percheron Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-73.14% / 3.93
=-18.61%

Percheron Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-71.80% / 3.28
=-21.89%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Percheron Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Percheron Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Percheron Therapeutics Business Description

Traded in Other Exchanges
Address
14 Wallace Avenue, LEVEL 1, Toorak, VIC, AUS, 3142
Percheron Therapeutics Ltd is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The company operates into two operating segment: ATL1102 and ATL1103. Key revenue is generated from ATL1102.

Percheron Therapeutics Headlines

No Headlines